How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Biagio Ricciuti, Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci, Luca Cantini, Andrea De Giglio, Giuseppe Lamberti, Chiara Ambrogio, Giulio Metro

Article Type

Review

Published

The authors review the current treatment landscape for patients with advanced non-small-cell lung cancers harbouring a KRAS G12C mutation, including PD-(L) 1-based therapies and direct KRAS inhibitors as well as sequential treatment options.

Read more

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

Daniele Marinelli, Marco Siringo, Giulio Metro, Biagio Ricciuti, Alain J Gelibter

Article Type

Review

Published

ALK-, ROS1- and NTRK-rearranged tumours represent a distinct clinical and molecular entity amongst non-small-cell lung cancer and have the highest frequency amongst young, non-smoker patients. This paper discusses ALK, ROS1 and NTRK-rearranged disease and all the available treatments are evaluated.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.